This surge in market value reflects a broader shift toward preventive healthcare, where omega-3 fatty acids—specifically EPA and DHA—are increasingly viewed as essential nutrients. Because the human body cannot synthesize these fats efficiently, reliance on fortified foods, dietary supplements, and pharmacy-grade preparations has become a global standard. Marine sources remain the primary supply chain, accounting for an estimated 93.6% of the market share in 2026.

Docosahexaenoic acid (DHA) continues to lead the segment, serving as a critical structural component of the brain and retina. Its integration into infant formula has become a major growth catalyst, bolstered by regulatory mandates in the European Union that require DHA inclusion in infant nutrition. Furthermore, North America currently holds the largest regional market share at 37%, while Europe maintains dominance through high consumer awareness and a robust regulatory framework supporting sustainable, clean-label alternatives.